|
The program was captured live at the NACE Emerging Challenges in Primary Care: Update 2007 series and features Dr. Fernando Ovalle. Dr. Ovalle, is the Associate Professor of Medicine, Director of the Clinical Research Unit, the Fellowship Training Program, Division of Endocrinology and Diabetes & Metabolism at the University of Alabama at Birmingham School of Medicine.
Learning Objective
The learning objective for this webcast is to decide when, how, and which insulin to start when managing patients with Type 2 Diabetes, and better understand available options for treating post-prandial hyperglycemia, as well as the role incretin hormones play in the management of diabetes.
Faculty Disclosure
Dr. Ovalle is affiliated with grants funded by GSK, Novo Nordisk, Pfizer, Sanofi-Aventis, Amylin, Eli Lilly, and AstraZeneca. He is on the speaker's bureau of GSK, Amgen, Eli Lilly, Novo Nordisk, Merck, and Pfizer.
Approximate running time 55 min.
Click here to view segment 1 of this webcast.
Click here to view segment 2 of this webcast.
|
